KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Long-Term Investments (2016 - 2025)

Globus Medical (GMED) has disclosed Long-Term Investments for 13 consecutive years, with $71.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 8.6% year-over-year to $71.8 million, compared with a TTM value of $71.8 million through Dec 2025, up 8.6%, and an annual FY2025 reading of $71.8 million, up 8.6% over the prior year.
  • Long-Term Investments was $71.8 million for Q4 2025 at Globus Medical, up from $16.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $562.5 million in Q4 2021 and bottomed at $12.3 million in Q3 2024.
  • Average Long-Term Investments over 5 years is $298.5 million, with a median of $411.7 million recorded in 2021.
  • The sharpest move saw Long-Term Investments soared 56.89% in 2021, then tumbled 95.54% in 2024.
  • Year by year, Long-Term Investments stood at $562.5 million in 2021, then fell by 11.84% to $495.9 million in 2022, then crashed by 84.79% to $75.4 million in 2023, then dropped by 12.32% to $66.1 million in 2024, then rose by 8.6% to $71.8 million in 2025.
  • Business Quant data shows Long-Term Investments for GMED at $71.8 million in Q4 2025, $16.7 million in Q3 2025, and $66.1 million in Q4 2024.